Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer

Clinical Cancer Research

Volumn 11, Issue 5, 2005, Pages 1757-1764

  Rich, Tyvin ^a   Innominato, Pasquale F ^b,c   Boerner, Julie ^a   Mormont, M Christine ^b   Iacobelli, Stefano ^c   Baron, Benoit ^d   Jasmin, Claude ^b   Lévi, Francis ^b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c UNIVERSITY OF CHIETI   (Italy)

^d EORTC DATA CENTER   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; HYDROCORTISONE; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA;

ACTIMETRY; ADULT; AGED; ANOREXIA; ARTICLE; BLOOD LEVEL; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; EMOTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; LIVER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; SOCIAL INTERACTION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; APPETITE; CIRCADIAN RHYTHM; COLORECTAL NEOPLASMS; FATIGUE; FEMALE; HUMANS; HYDROCORTISONE; INTERLEUKIN-6; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; PROSPECTIVE STUDIES; QUALITY OF LIFE; SLEEP; SOCIAL BEHAVIOR; SURVIVAL ANALYSIS; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 16344373564     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2000     Document Type: Article

References (50)

1. Maisey NR, Norman A, Watson M, Allen MJ, Hill ME, Cunningham D. Baseline quality of life predicts survival in patients with advanced colorectal cancer. Eur J Cancer 2002;38:1351-7.
2. Coates A, Porzsolt F, Osoba D. Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. Eur J Cancer 1997;33:1025-30.
3. Montazeri A, Milroy R, Hole D, McEwen J, Gillis CR. Quality of life in lung cancer patients: as an important prognostic factor. Lung Cancer 2001;31:233-40.
4. Chevalier V, Mormont MC, Cure H, Chollet P. Assessment of circadian rhythms by actimetry in healthy subjects and patients with advanced colorectal cancer. Oncol Rep 2003;10:733-7.
5. Mormont MC, Waterhouse J, Bleuzen P, et al. Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res 2000;6:3038-45.
6. Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst 2000;92:994-1000.
7. Levi F. Circadian chronotherapy for human cancers. Lancet Oncol 2001;2:307-15.
8. Cleeland CS, Bennett GJ, Dantzer R, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer 2003;97:2919-25.
9. Dantzer R. Cytokine-induced sickness behavior: mechanisms and implications. Ann N Y Acad Sci 2001;933:222-34.
10. Haddad JJ, Saade NE, Safieh-Garabedian B. Cytokines and neuroimmune-endocrine interactions: a role for the hypothalamic-pituitary- adrenal revolving axis. J Neuroimmunol 2002;133:1-19.
11. Harbuz MS, Chover-Gonzalez AJ, Jessop DS. Hypothalamo-pituitary-adrenal axis and chronic immune activation. Ann N Y Acad Sci 2003;992:99-106.
12. Hermus AR, Sweep CG. Cytokines and the hypothalamic-pituitary-adrenal axis. J Steroid Biochem Mol Biol 1990;37:867-71.
13. Johnson RW. The concept of sickness behavior: a brief chronological account of four key discoveries. Vet Immunol Immunopathol 2002;87:443-50.
14. Larson SJ, Dunn AJ. Behavioral effects of cytokines. Brain Behav Immun 2001;15:371-87.
15. Miller AH. Cytokines and sickness behavior: implications for cancer care and control. Brain Behav Immun 2003;17 Suppl 1:S132-4.
16. Mormont MC, Langouet AM, Claustrat B, et al. Marker rhythms of circadian system function: a study of patients with metastatic colorectal cancer and good performance status. Chronobiol Int 2002;19:141-55.
17. Mormont MC, Hecquet B, Bogdan A, Benavides M, Touitou Y, Levi F. Non-invasive estimation of the circadian rhythm in serum cortisol in patients with ovarian or colorectal cancer. Int J Cancer 1998;78:421-4.
18. Mormont MC, Waterhouse J. Contribution of the rest-activity circadian rhythm to quality of life in cancer patients. Chronobiol Int 2002;19:313-23.
19. Carroll BT, Kathol RG, Noyes R Jr, Wald TG, Clamon GH. Screening for depression and anxiety in cancer patients using the Hospital Anxiety and Depression Scale. Gen Hosp Psychiatry 1993;15:69-74.
20. Kronfol Z, Remick DG. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 2000;157:683-94.
21. Raison CL, Miller AH. Depression in cancer: new developments regarding diagnosis and treatment. Biol Psychiatry 2003;54:283-94.
22. Turnbull AV, Rivier CL. Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. Physiol Rev 1999;79:1-71.
23. Moskal TL, Huang S, Ellis LM, Fritsche HA Jr, Chakrabarty S. Serum levels of transforming growth factor α in gastrointestinal cancer patients. Cancer Epidemiol Biomarkers Prev 1995;4:127-31.
24. Capuron L, Ravaud A, Dantzer R. Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon α-2b therapy. J Clin Oncol 2000;18:2143-51.
25. Spath-Schwalbe E, Hansen K, Schmidt F, et al. Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. J Clin Endocrinol Metab 1998;83:1573-9.
26. Lutgendorf SK, Johnsen EL, Cooper B, et al. Vascular endothelial growth factor and social support in patients with ovarian carcinoma. Cancer 2002;95:808-15.
27. Musselman DL, Miller AH, Porter MR, et al. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry 2001;158:1252-7.
28. Komoda H, Tanaka Y, Honda M, Matsuo Y, Hazama K, Takao T. Interleukin-6 levels in colorectal cancer tissues. World J Surg 1998;22:895-8.
29. Chung YC, Chang YF. Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol 2003;83:222-6.
30. Mosesson Y, Yarden Y. Oncogenic growth factor receptors: implications for signal transduction therapy. Semin Cancer Biol 2004;14:262-70.
31. Fan X, Childs GV. Epidermal growth factor and transforming growth factor-α messenger ribonucleic acids and their receptors in the rat anterior pituitary: localization and regulation. Endocrinology 1995;136:2284-93.
32. Fan X, Nagle GT, Collins TJ, Childs GV. Differential regulation of epidermal growth factor and transforming growth factor-α messenger ribonucleic acid in the rat anterior pituitary and hypothalamus induced by stresses. Endocrinology 1995;136:873-80.
33. Kramer A, Yang FC, Snodgrass P, et al. Regulation of daily locomotor activity and sleep by hypothalamic EGF receptor signaling. Science 2001;294:2511-5.
34. Ferrer I, Alcantara S, Ballabriga J, et al. Transforming growth factor-α (TGF-α) and epidermal growth factor-receptor (EGF-R) immunoreactivity in normal and pathologic brain. Prog Neurobiol 1996;49:99-123.
35. Junier MP. What role(s) for TGFα in the central nervous system? Prog Neurobiol 2000;62:443-73.
36. De Jong KP, Stellema R, Karrenbeld A, et al. Clinical relevance of transforming growth factor α, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors. Hepatology 1998;28:971-9.
37. Hastings MH, Reddy AB, Maywood ES. A clockwork web: circadian timing in brain and periphery, in health and disease. Nat Rev Neurosci 2003;4:649-61.
38. Dunlap JC. Molecular bases for circadian clocks. Cell 1999;96:271-90.
39. Reppert SM, Weaver DR. Coordination of circadian timing in mammals. Nature 2002;418:935-41.
40. Hilakivi-Clarke L. Overexpression of transforming growth factor α in transgenic mice alters nonreproductive, sex-related behavioral differences: interaction with gonadal hormones. Behav Neurosci 1994;108:410-7.
41. Hilakivi-Clarke LA, Arora PK, Sabol MB, Clarke R, Dickson RB, Lippman ME. Alterations in behavior, steroid hormones and natural killer cell activity in male transgenic TGF ́ mice. Brain Res 1992;588:97-103.
42. Hilakivi-Clarke LA, Arora PK, Clarke R, Wright A, Lippman ME, Dickson RB. Opposing behavioural alterations in male and female transgenic TGF ́ mice: association with tumour susceptibility. Br J Cancer 1993;67:1026-30.
43. Kastin AJ, Pan W, Maness LM, Banks WA. Peptides crossing the blood-brain barrier: some unusual observations. Brain Res 1999;848:96-100.
44. Pan W, Kastin AJ. Entry of EGF into brain is rapid and saturable. Peptides 1999;20:1091-8.
45. Pan W, Vallance K, Kastin AJ. TGFα and the blood-brain barrier: accumulation in cerebral vasculature. Exp Neurol 1999;160:454-9.
46. Sephton S, Spiegel D. Circadian disruption in cancer: a neuroendocrine-immune pathway from stress to disease? Brain Behav Immun 2003;17:321-8.
47. Fu L, Pelicano H, Liu J, Huang P, Lee C. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 2002;111:41-50.
48. Filipski E, King VM, Li X, et al. Host circadian clock as a control point in tumor progression. J Natl Cancer Inst 2002;94:690-7.
49. Filipski E, Delaunay F, King VM, et al. Effects of chronic jet lag on tumor progression in mice. Cancer Res 2004;64:7879-85.
50. Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, Okamura H. Control mechanism of the circadian clock for timing of cell division in vivo. Science 2003;302:255-9.